Expression of FLIPLong and FLIPShort in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: Correlation with apoptosis

Leukemia

Volumn 17, Issue 12, 2003, Pages 2460-2466

  Benesh, M ^a   Platzbecker, U ^a   Ward, J ^a   Deeg, H J ^a,b   Leisenring, W ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Apoptosis; FLIPLong; FLIPShort; Myelodysplasia

Indexed keywords

CD34 ANTIGEN; FLICE INHIBITORY PROTEIN; RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; VOLUNTEER;

EID: 0346025550     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403180     Document Type: Article

References (36)

1. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
2. Parker JE, Mufti GJ. Excessive apoptosis in low risk myelodysplastic syndromes (MDS) [Review]. Leukemia Lymphoma 2000; 40: 1-24.
3. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
4. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11: 839-845.
5. Shetty V, Hussaini S, Broady-Robinson L, Allampallam K, Mundle S, Borok R et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000; 96: 1388-1392.
6. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932-3938.
7. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily [Review]. Nat Rev Cancer 2002; 2: 420-430.
8. Niho Y, Asano Y. Fas/Fas ligand and hematopoietic progenitor cells [Review]. Curr Opin Hematol 1998; 5: 163-165.
9. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms [Review]. Curr Opin Immunol 1998; 10: 559-563.
10. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998; 12: 486-492.
11. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A et al. A role for tumor necrosis factor-α, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103: 176-188.
12. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049-2054.
13. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001; 98: 3058-3065.
14. Tschopp J, Irmler M, Thome M. Inhibition of fas death signals by FLIPs [Review]. Curr Opin Immunol 1998; 10: 552-558.
15. Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice [Review]. Immunity 1999; 10: 629-639.
16. Bin L, Li X, Xu LG, Shu HB. The short splice form of casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett 2002; 510: 37-40.
17. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274: 1541-1548.
18. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002; 277: 25020-25025.
19. Chung IJD. Stem cell factor increases the expression of FLIP that inhibits IFNgamma -induced apoptosis in human erythroid progenitor cells. Blood 2003; 101: 1324-1328.
20. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002; 21: 3704-3714.
21. Hu ZB, Ma W, Zaborski M, MacLeod R, Quentmeier H, Drexler HG. Establishment and characterization of two novel cytokine-responsive acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3. Leukemia 1996; 10: 1025-1040.
22. Span LF, Dar SE, Shetty V, Mundle SD, Broady-Robinson L, Alvi S et al. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia. Leukemia 1998; 12: 1685-1695.
23. Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leukemia Lymphoma 2000; 37: 405-414.
24. Platzbecker U, Ward JL, Deeg HJ. Chelerythrin activates caspase-8, downregulates FLIP long and short, and overcomes resistance to TRAIL (TNF-related apoptosis inducing ligand) in KG1a cells. Br J Haematol 2003; 122: 1-9.
25. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 1997; 11: 656-659.
26. Ali A, Mundle SD, Ragasa D, Reza S, Shetty V, Mativi BY et al. Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res 1999; 8: 343-356.
27. Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999; 140: 201-207.
28. Bouscary D, Chen YL, Guesnu M, Picard F, Viguier F, Lacombe C et al. Activity of the caspase-3/CPP32 enzyme is increased in 'early stage' myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp Hematol 2000; 28: 784-791.
29. Kim H, Whartenby KA, Georgantas RW, Wingard J, Civin CI. Human CD34+ hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. Stem Cells 2002; 20: 174-182.
30. Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002; 277: 45162-45171.
31. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 2001; 276: 20633-20640.
32. Kirchhoff S, Muller WW, Li-Weber M, Krammer PH. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur J Immunol 2000; 30: 2765-2774.
33. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21: 5299-5305.
34. Park SJ, Kim YY, Ju JW, Han BG, Park SI, Park BJ. Alternative splicing variants of c-FLIP transduce the differential signal through the Raf or TRAF2 in TNF-induced cell proliferation. Biochem Biophys Res Commun 2001; 289: 1205-1210.
35. Wu XC, Asselin E, Tsang BK. Nuclear factor kappaB-mediated induction of Flice-like inhibitory protein prevents tumor necrosis factor alpha-induced apoptosis in rat granulosa cells. Biol Reprod 2002; 67: 436-441.
36. Xiao CW, Yan X, Li Y, Reddy SA, Tsang BK. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology 2003; 144: 623-630.